CHX 108
Latest Information Update: 02 Jul 2023
At a glance
- Originator Access Pharmaceuticals
- Developer GSK; PlasmaTech Biopharmaceuticals
- Class Antiallergics; Antipruritics; Antipsoriatics
- Mechanism of Action Cyclooxygenase inhibitors; Lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 05 Dec 2001 Discontinued-II for Psoriasis in USA (Unknown route)
- 07 Nov 2000 No-Development-Reported for Psoriasis in USA (Unknown route)
- 20 Aug 1997 Investigation in Psoriasis in USA (Unknown route)